In search of lost biomarker for immunotherapy in small cell lung cancer
Chemo-immunotherapy is the current standard of care for extensive-stage small cell lung
cancer, but predictive biomarkers are lacking. In a recent article, the authors report the …
cancer, but predictive biomarkers are lacking. In a recent article, the authors report the …
[HTML][HTML] Recent advances and future strategies in first-line treatment of ES-SCLC
I Gomez-Randulfe, R Leporati, B Gupta, S Liu… - European Journal of …, 2024 - Elsevier
Recent advancements in treating extensive-stage small-cell lung cancer (ES-SCLC) have
been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum …
been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum …
[HTML][HTML] The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics
P Trillo Aliaga, E Del Signore, V Fuorivia, G Spitaleri… - Genes, 2024 - mdpi.com
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma accounting for
15% of lung cancers with dismal survival outcomes. Minimal changes in therapy and …
15% of lung cancers with dismal survival outcomes. Minimal changes in therapy and …
[HTML][HTML] Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs
Y Jiang, H Zhou, J Liu, W Ha, X Xia, J Li, T Chao… - Pharmaceuticals, 2024 - mdpi.com
Precise targeting has become the main direction of anti-cancer drug development.
Trophoblast cell surface antigen 2 (Trop-2) is highly expressed in different solid tumors but …
Trophoblast cell surface antigen 2 (Trop-2) is highly expressed in different solid tumors but …